PWSA Blog

Important Update for the PWS Community: HERO Phase 3 Trial for ARD-101 Voluntarily Paused

We would like to share an important update from Aardvark Therapeutics.

Aardvark has announced a voluntary pause of the Phase 3 HERO clinical trial, which is evaluating ARD‑101 for the treatment of hyperphagia in people with Prader‑Willi syndrome. The decision to pause the trial is based on reversible cardiac observations identified in a non-PWS, separate healthy volunteer study at higher‑than‑target therapeutic doses during routine safety monitoring. Aardvark is conducting a comprehensive review of the data to help determine next steps. Out of an abundance of caution, the company has paused ongoing enrollment and dosing in the HERO trial while this evaluation is underway.

We understand that news like this can feel disappointing and unsettling. Clinical research is complex, and while pauses are difficult, they are sometimes necessary to ensure studies proceed safely, thoughtfully, and responsibly.

If you or your family member is participating in the HERO trial, please continue to direct any immediate questions to your clinical trial site. We expect to share details soon about a community conversation next week, which will provide space for questions, share what we currently know, and discuss what this update means for the PWS community. Please stay tuned for additional information.

We will continue to keep you informed as more information becomes available.

For additional details, you can read the full announcement at the button below.

Share this!

Scroll to top